Adverum Biotechnologies Hosts Webcast To Review Clinical Data From The 26-Week Interim Analysis Of The Ongoing LUNA Phase 2 Trial In Wet AMD, Presented At ASRS Annual Meeting On Wednesday, July 17 at 8:00 a.m. ET

Author: Benzinga Newsdesk | July 10, 2024 08:14am

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Research, Retina Consultants of Texas, Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, and principal investigator in the LUNA study.

Posted In: ADVM